sorry - didn't notice your commentary at first:
"Regimens including two or more direct antiviral agents will not be part of the SoC until 2011 because it will be difficult for companies to run clinical trials on combinations of unapproved drugs."
I'm sure you are right, although someone did post an analyst opinion about a possible combination trial of vx-950 with a polymerase inhibitor..not sure of the credibility of this opinion
http://www.investorshub.com/boards/read_msg.asp?Message_id=15146739&txt2find=polymerase
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
